Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.

Aging CellSep 24, 2026
Clinical ResearchGeriatricsInfectious Diseases

Tingting Xia, Hongmei Wu, Tianyi Cui et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of Polygonatum odoratum on gut microbiota and immune profiles in 140 community-dwelling older adults aged 60 and above over 90 days. The study found that the intervention led to a reduction in certain T cell subsets and an increase in beneficial gut bacteria, suggesting a link between gut health and immune function in aging individuals.

Key findings

  • After 90 days, the percentage of TEMRA and CD28 - CD57 + TEMRA cells were reduced in elderly subjects.
  • The relative abundance of Prevotella 9 and Akkermansia increased, while Klebsiella significantly decreased.
  • Correlation analysis linked YZG-induced gut microbiota changes to improved immunity and fewer respiratory infections.

Why it matters

Understanding the relationship between gut microbiota and immune function in older adults can inform strategies to enhance health and reduce infection risk in this vulnerable population.

Source

PubMed · PMID 42775700

Published in Aging Cell. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.